PT-141 (bremelanotide): adverse events and evidence limits
During the 24-week core trials of subcutaneous bremelanotide in premenopausal women with HSDD, nausea, flushing and headache were more common than with placebo. [1]
Investigators also described drug-related vomiting/headache requiring hospitalization. This does not establish catalog-reagent risks. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Nausea | Premenopausal women with HSDD, subcutaneous bremelanotide, 24-week core trial phase | More common than with placebo; no percentage given in the abstract | [1] |
| Flushing | The same participants | More common than with placebo; no frequency given | [1] |
| Headache | The same participants | More common than with placebo; no frequency given | [1] |
| Vomiting/headache requiring hospitalization | The same participants | Described by investigators as drug-related | [1] |
References
- Sheryl A Kingsberg et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. 10.1097/AOG.0000000000003500.